Press Releases

    • APR 16 2018

    Clinical Trial Tests ONC201 in Combination with Ixazomib and Dexamethasone in Multiple Myeloma

    Philadelphia, PA (April 16, 2018) – Oncoceutics, Inc. announced today that the first patient has been treated in a Phase I/II clinical trial of ONC201 in combination with ixazomib and dexamethasone in relapsed and/or refractory multiple myeloma. The trial, led by Ajai Chari, MD, Associate Professor at the Icahn School of Medicine at Mount Sinai,

    • APR 05 2018

    ONC201 Trial Begins for Endometrial and Breast Cancer

    Philadelphia, PA (April 5, 2018) – Oncoceutics, Inc. announced today that the first patient has been treated in a clinical trial of ONC201 for patients with certain types of advanced endometrial and breast cancer. The Phase II trial is led by Alexandra Zimmer, MD, Assistant Research Physician at the Women’s Malignancies Branch at the National

    • MAR 19 2018

    Abstracts at AACR Describe Unique Way that ONC201 Kills Dopamine-Dysregulated Tumors

    Philadelphia, PA (March 19, 2018) – Oncoceutics, Inc. announced that multiple abstracts from the company and its commercial and academic collaborators will be presented at the 2018 annual meeting of the American Association of Cancer Research (AACR) in Chicago, Illinois, on April 14th to April 18th. These abstracts highlight the unique way that ONC201 engages the

    • FEB 14 2018

    Oncoceutics and Calvert Research Announce Development/Investment Agreement for ONC 206

    Philadelphia, PA (February 14, 2018) – Oncoceutics Inc. and Calvert Research, LLC announced that the two companies have entered into a second product development and investment partnership agreement, this time to further develop and enable the submission of an investigational new drug (IND) application for ONC206, Oncoceutics’ next generation molecule. As a part of this